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Background: Adenomatous polyposis coli (APC) has been reported to be a candidate tumor suppressor in many
cancers. However, the diagnostic role of APC promoter methylation in non-small cell lung cancer (NSCLC) remains
unclear. We systematically integrated published articles and DNA methylation microarray data to investigate the
diagnostic performance of the APC methylation test for NSCLC. Two thousand two hundred and fifty-nine NSCLC
tumor samples and 1,039 controls were collected from 17 published studies and TCGA NSCLC data. The association
between APC promoter methylation and NSCLC was evaluated in a meta-analysis. An independent DNA methylation
microarray dataset from TCGA project, in which five CpG sites located in the promoter region of APC were involved,
was used to validate the results of the meta-analysis.
Results: A significant association was observed between APC promoter hypermethylation and NSCLC, with
an aggregated odds ratio (OR) of 3.79 (95% CI: 2.22 to 6.45) in a random effects model. Pooled sensitivity and
specificity were 0.548 (95% CI: 0.42 to 0.67, P < 0.0001) and 0.776 (95% CI: 0.62 to 0.88, P < 0.0001), respectively.
Each of the five CpG sites was much better in prediction (area under the curve, AUC: 0.71 to 0.73) in lung
adenocarcinoma (Ad) than in lung squamous cell carcinoma (Sc) (AUC: 0.45 to 0.61). The AUCs of the logistic
prediction model based on these five CpGs were 0.73 and 0.60 for Ad and Sc, respectively. Integrated analysis
indicated that CpG site location, heterogeneous or autogenous controls, and the proportion of adenocarcinoma
in samples were the most significant heterogeneity sources.
Conclusions: The methylation status of APC promoter was strongly associated with NSCLC, especially adenocarcinoma.
The APC methylation test could be applied in the clinical diagnosis of lung adenocarcinoma.
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Non-small cell lung cancer (NSCLC), including adenocar-
cinoma (Ad) and squamous cell carcinoma (Sc), is the
leading cause of cancer death in both men and women in
the United States [1]. Over 159,480 Americans die of this
disease every year in the US [1]. The five-year relative
survival rate varies markedly depending on the stage at
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unless otherwise stated.regional, and distant stage disease, respectively (SEER
Cancer Statistics Review 1975 to 2002). However, the
bottleneck in improving survival is early detection [2].
As an important mechanism for tumor suppressor gene
inactivation in cancer, DNA hypermethylation could
yield powerful biomarkers for early detection of lung
cancer, owning incomparable advantages over other
traditional markers due to its stable chemical property,
detection ability in remote patient media, quantitative
signal, convenient low cost in detection, and so on [3].
Several revolutionary steps have been made to promote
application of methylation biomarkers in cancer screening. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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become a powerful tool for lung cancer diagnosis.
The APC gene encodes a tumor suppressor protein
that acts as an antagonist of the Wnt signaling pathway,
and it also participates in cell migration and adhesion,
transcriptional activation, and apoptosis [6]. Meanwhile,
defects in the APC gene cause familial adenomatous
polyposis (FAP), an autosomal dominant pre-malignant
disease that usually progresses to malignancy, suggesting
that APC could be a potential predictor for cancer initi-
ation or development. Researchers have reported that
promoter methylation, which inhibits APC gene expres-
sion, is mediated by changes of chromatin conformation
and aberrant binding of CCAAT-box binding transcrip-
tion factors [7].
Like P16INK4A [8], the relationship between hyperme-
thylation of APC with cancers has also been extensively
estimated [9] and APC promoter hypermethylation in
NSCLC has been reported as an effective biomarker for
diagnosis [10,11]. However, the results appear dramatically
different among different research studies, and this may
be caused by the difference in gender proportion, age
distribution, racial source, certain other epidemiological
characteristics in samples, detection methods, and so on.
In addition, there has not yet been any quantitative assess-
ment of the relationship between hypermethylation in the
promoter region of the APC gene and NSCLC.
In this article, we conducted a meta-analysis of the
sensitivity and specificity of APC methylation on NSCLC
diagnosis. The factors which lend heterogeneity to the
sensitivity and specificity were identified with meta-
regression. We also found that The Cancer Genome
Atlas project (TCGA) had collected hundreds of whole
genome DNA methylation microarray datasets of NSCLC
samples which included comprehensive clinical and demo-
graphic information, providing an additional resource that
may be without publication bias. In our work, we innova-
tively integrated these TCGA data (Additional file 1: Table
S1) and the data from published articles to evaluate the
diagnostic ability of the APC methylation test in NSCLC.
Therefore, an integrated analysis of all these existing data
was conducted to come to unbiased conclusions on the
relationship between APC methylation and NSCLC.
Results
Study characteristics
The electronic search strategy identified 506 potentially
relevant articles (PubMed, 315; Scopus, 112; Cochrane
Library, 3; OVID Medline, 53; TMC ProSearch, 23),
which were further screened for inclusion on the basis
of their titles, abstracts, full texts, or a combination of
these terms. The electronic search was supplemented
from reference lists of relevant articles including reviews.
Finally, 17 studies with data on the relationship betweenAPC gene promoter methylation and NSCLC were pooled
for analysis (Table 1) [10,12-27]. All these articles were
written in English. In total, 1,338 lung cancer tissues/
serum and 913 normal counterpart tissues/serum were
collected. The age of the subjects in the 17 studies ranged
from 25 to 86 years, with mean or median ranging from
53 to 67 years. As for the study aim, 13 articles were
especially aiming at diagnosis, while the others were for
prognosis, survival research, and so on. Among 17 studies,
the proportions of stage I samples differed from 32.1 to
100%, and the percentage of male individuals in the
NSCLC samples has a range of 53 to 81%. For the
experimental methods to explore APC promoter methyla-
tion status, 7 of 17 inclusions used methylation-specific
polymerase chain reaction (MSP), while others used quan-
titative MSP (qMSP, such as Methylight, Prosequencing,
and so on). Two kinds of methylation detection primers
or probes were found to be utilized for most of the 17
studies. The information of the two sets of primers (set I:
chr5:112073421-112073518, seven studies; and set II:
chr5:112101379-112101452, seven studies) is listed in
Additional file 1: Table S2. Although no CpG sites from
the methylation microarrays were found located in the
above primers, cg20311501 is covered by the replication
region of set II primers.
Meta-analysis, subgroup analysis and meta-regression
The ORs for APC methylation in cancer tissues compared
with that in normal controls were 4.67 (95% CI: 2.66 to
8.22, z = 5.35, P < 0.0001) in random effects model pooled,
and 2.74 (95% CI: 1.99 to 3.23, z = 8.10, P < 0.0001) in
fixed effects model, demonstrating a statistically significant
increasing in likelihood of methylation in lung cancer
tissues comparing to controls (Figure 1).
Subgroup analyses were conducted for different subtypes,
which included sample types (tissue or serum), counterpart
categories (autogenous or heterogeneous), proportion of
stage I, aim of the study (for diagnosis or non-diagnosis),
ratio of adenocarcinoma to squamous (Ad2Sc), primer
categories (sets I and II) (Additional file 1: Table S2) and
other possible confounding factors (Table 2). Significant
differences were found between the ORs of the younger
(5.03, 95% CI: 2.53 to 10.0) and older (0.91, 95% CI: 0.57
to 1.41) subgroup (P < 0.0001) (Figure 2A). The group
with the high proportion of adenocarcinoma had a
significantly bigger OR than that of the low subgroup
(P = 0.0077) which suggested that APC methylation
might have subtype specificity in NSCLC (Figure 2C).
Significant difference was also found between primer
sets I and II (P = 0.0137), which supported primers as
being one of the most important heterogeneity sources
in the APC methylation test (Figure 2D). Both tissue
and serum groups showed significant association be-
tween APC methylation and NSCLC (OR = 3.72, 11.54,
Table 1 Characteristics of eligible studies considered in the report
Author Sample
type











Zhang et al. [27]b Tissue 59 32.05 29/39 44/34 10/68 MSP Diagnose Yes 0.83 hom [27]
Wang et al. [25] Tissue - - 17/28 19/9 1/11 qMSP Diagnose Yes 2.14 heter [25]
Jin et al. [15] Tissue 66.7 - 17/24 27/45 22/41 qMSP Non-diagnose Yes 1.87 heter [15]
Feng et al. [14] Tissue 64.3 42.86 26/49 26/23 21/28 qMSP Diagnose Yes 1.43 hom [14]
Brabender et al. [13] Tissue 63.3 49.45 69/91 86/5 80/11 qMSP Non-diagnose Single 0.77 hom [13]
Virmani et al. [24] Tissue - - - 22/26 0/18 MSP Diagnose Yes NA heter [24]
Yanagawa et al. [26] Tissue 67.3 66.67 18/25 28/47 36/39 MSP Diagnose Yes 1.48 hom [26]
Topaloglu et al. [22] Tissue - 54.84 - 17/14 5/17 qMSP Diagnose Yes 3.00 heter [22]
Kim et al. [16] Tissue 63 56.57 64/79 48/41 33/66 MSP Non-diagnose Yes 0.62 hom [16]
Vallbohmer et al. [23] Tissue 63 49.45 69/91 86/5 80/3 PCR Non-diagnose Yes 0.77 hom [23]
Lin et al. [17] Tissue 61.1 100.00 20/31 49/75 2/24 MSP Diagnose Yes 1.84 heter [17]
Shivapurkar et al. [20] Tissue - - - 35/5 23/17 qMSP Diagnose Yes 1.22 heter [20]
Suzuki et al. [21] Tissue 64 34.00 33/49 53/97 3/57 MSP Non-diagnose Yes NA heter [21]
Zhang et al. [27]b Serum - - - 54/56 5/45 MSP Diagnose Yes NA heter [27]
Pan et al. [18] Serum 53 - 17/26 40/38 0/31 qMSP Diagnose Single NA heter [18]
Begum et al. [12] Serum 65 - 10/19 12/64 3/27 qMSP Diagnose Yes NA heter [12]
Rykova et al. [19] Serum NA - - 3/6 0/16 MSP Diagnose Yes NA heter [19]
Usadel et al. [10] Serum 64.2 - - 42/47 0/50 qMSP Diagnose Single NA heter [10]
amean or median age from articles; bwith two records since there are Tissue and serum data simultaneously in this article. M + and M- means methylation
positive and methylation negative, respectively.
Abbreviations: Ad2Sc, the ratio of adenocarcinoma to squamous cell carcinoma; hom, homogeneous control; heter, heterogeneous control. MSP, qualitative
methylation detection method; qMSP, quantitative detection method; Sample type represents the samples analyzed.
Guo et al. Clinical Epigenetics 2014, 6:5 Page 3 of 11
http://www.clinicalepigeneticsjournal.com/content/6/1/5respectively) which suggested that APC methylation can
be taken as a potential biomarker for NSCLC diagnosis
using either tissue or serum samples. In addition, signifi-
cant differences were found between the ORs of heteroge-
neous (ORh = 8.33, 95% CI: 3.77 to 18.39) and autogenous
(ORa = 2.25, 95% CI: 1.06 to 4.77) subgroups (P = 0.0187)
(Figure 2B). One possible reason might be the impure
composition of the adjacent normal specimens which
might have been slightly contaminated by cancer cells,
or it have been transformed to precancerous status,
while normal serum samples generally came from healthy
individuals. The subgroup of high Ad2Sc had a larger OR
than that of low Ad2Sc (Table 2), indicating that methyla-
tion of APC might have occurred or functioned at the
early stage of tumorigenesis, which had been found for
endometrial cancer [28]. The OR in studies aiming at
diagnosis (OR = 6.79) is more than 2.6 times the OR in the
non-diagnosis group (OR = 2.59), which might be caused
by an unbalanced distribution in the proportion of early
stage samples (P = 0.0218, Wilcoxon rank-sum test). No
significant difference was found between subgroups of
MSP and qMSP (P = 0.77), which suggested both of the
methods were equivalent in methylation detection (Table 2)
and the result was consistent with Wu’s conclusion [29].
Meta-regression revealed that heterogeneity exists among
17 studies (I2 = 79.2%, Q = 52.78, P < 0.0001) (Figure 1),whereas age and primer sets were the major source of
heterogeneity. The trend in ORs was inversely correlated
with age (beta = −0.3, P = 2.0 × 10−5), and age counted
for 83.8% total variances. This result is consistent with
the subgroup analysis, in which the OR of the older
group (OR = 2.24) was smaller than the younger group
(OR = 4.65). The primer set is also an important hetero-
geneity source (P = 0.05), explaining about 68% of overall
heterogeneity. Other factors such as sample type, propor-
tion of males, proportion of stage I and detection methods
fail to explain the heterogeneity counting for type I error
at level of 0.05 (Table 3).
Summary receiver operating characteristic curve for
diagnostic capacity of APC methylation
Pooled sensitivity and specificity were 0.548 (95% CI:
0.42 to 0.67, P < 0.0001) and 0.78 (95% CI: 0.62 to 0.88,
P < 0.0001) for all the studies based on the presupposition
of the fixed effects model. The sensitivity of the tissue
group was higher than that of the serum group, 0.61 (0.45
to 0.75) versus 0.396 (0.26 to 0.56), while the specificity
of the serum group was higher than that of the tissue
group, 0.92 (0.86 to 0.96) versus 0.68 (0.49 to 0.83),
which suggested the advantage of this biomarker for its
higher diagnostic ability using remote non-invasive media.
Figure 1 Combined estimates for the association between APC promoter hypermethylation and non-small cell lung cancer (NSCLC)
with forest plot. Author, year, country of the studies and methylated (M) and total number of the sample (T) in case and control, combined
odds ratio (OR) with 95% confidence region were labeled in the left column of the figure. The DerSimonian-Laird estimator and Mantel-Haenszel
method were selected to conduct combination estimation for the random effects model and fixed effects model, respectively.
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important features of a diagnostic test, in some occasions,
pooling sensitivity or specificity could be misleading as
mentioned in the Methods section. Therefore, we con-
structed the summery receiver operating characteristic
(SROC) curve to depict the stability and accuracy of
the methylation test’s diagnostic ability. The area under
the curve (AUC) of the SROC was 0.64, suggesting a fair
ability for NSCLC diagnosis (Figure 2F). Meanwhile, the
AUC of the SROC for the serum and the tissue group was
0.67 and 0.64 respectively, showing slightly different
performances for the APC methylation test in serum and
tissue samples.
Bias analysis and robust estimation of pooled OR
A funnel plot of methylation status of lung cancer tissue
versus normal tissue showed significant publication bias
(Egger test, z = 4.3, P < 0 .0001) and eight studies exceeded
the 95% confidence limits (Additional file 2: Figure S1). In
order to eliminate the effect of publication bias, trim and
fill analysis was performed with the random effects model.
The adjusted pooled OR were 2.50 (95% CI: 1.43 to 4.38,
P = 0.0013) in the random effects model and 2.19 (95%
CI: 1.74 to 2.77, P < 0.0001) in the fixed effects model.
Both results demonstrate a significantly positive associationbetween APC methylation and NSCLC (Additional file 2:
Figure S2).
In sensitivity analysis to determine the effect of omitting
a single study on the overall effect, the overall ORs were
between 4.3 (95% CI: 2.46 to 7.52) and 5.27 (95% CI: 2.92
to 9.53) in the random effects method, which suggested
that combined OR was consistent and reliable (Additional
file 2: Figure S3).
A cumulative meta-analysis at the time of the published
literature was also conducted, and we found the OR was
tending to be stable (Figure 2E). The stable result indicates
our meta-analysis might be more credible when more
incoming researches are added.
Using similar methodology, the influence on meta-
regression was determined by omitting one study each
time to explore heterogeneity sources. The sample type
of tissue or serum would be one of the heterogeneity
sources (P < 0.026) when Begum et al. ([12], US) were
removed from the meta studies; likewise, the proportion
of stage I and aim of the study would become the hetero-
geneity source when Lin et al. ([17], China), Zhang et al.
([27], China) or Yanagawa et al. ([26], Japan) was removed
(P-values were 0.0046, 0.029 and 0.039 respectively). This
analysis suggested the above factors should be considered
in a future case-control association study.
Table 2 Subgroup analysis for the main potential confounding factors with random effects model
Subgroup Number of study OR 95% CI Q I2 P-value
Overall 18 4.67 2.65 to 8.21 73.99 77.00%
Age ≤ 65 9 5.03 2.53 to 10.0 27.96 71.40%
Age > 65 3 0.91 0.57 to 1.41 2.21 9.400% < 0.0001
Stage I > 49.5% 5 4.11 1.90 to 8.91 12.76 68.60%
Stage I ≤ 49.5% 4 2.81 0.87 to 9.09 19.42 84.60% 0.5944
M2F≤ 69% 6 5.98 2.04 to 17.53 16.66 70.00%
M2F > 69% 6 2.13 0.99 to 4.55 29.05 82.80% 0.1246
MSP 8 5.16 2.01 to 13.26 44.61 84.30%
qMSP 10 4.32 2.08 to 8.94 29.28 69.30% 0.7685
Diagnose 13 6.79 2.99 to 15.44 59.54 79.80%
Non-diagnose 5 2.59 1.33 to 5.05 11.56 65.40% 0.0745
Multiple targets 15 4.08 2.28 to 7.34 62.99 77.80%
Single target 3 18.72 1.23 to 283 9.03 77.80% 0.2836
Heterogeneous 12 8.33 3.77 to 18.39 35.71 69.20%
Autogenous 6 2.25 1.06 to 4.77 27.19 81.60% 0.0187
Serum 5 11.54 2.87 to 46.40 10.4 61.50%
Tissue 13 3.72 2.03 to 6.78 55.18 78.30% 0.14
Ad2Sc < 2 9 2.46 1.35 to 4.48 35.79 77.00%
Ad2Sc > = 2 2 17.1 4.68 to 62.7 0.11 0.000% 0.0077
Primer set I 5 5.41 2.43 to 12.04 13.71 70.80%
Primer set II 4 1.82 1.05 to 3.13 4.57 34.30% 0.0137a
Bold P-values lower than 0.05 indicate significant differences between groups (random effects model, d.f. = 1).
aThe serum groups and the studies with less than 50 samples were removed.
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In order to make independent validation of the above
results, we collected the data of the methylation status
of six CpG sites located in the promoter region of the
APC gene from the lung cancer samples of TCGA project
(Additional file 1: Table S1). Pairwise methylation Pearson
correlation analysis showed that the methylation status
was highly correlated among these CpG sites (R2 > 0.90 for
all) except cg01240931 (R2 < 0.45 for all), which suggested
that cg01240931 was out of the ‘methylation block’ com-
posed of the other five CpG sites. Meanwhile, cg01240931
was hypermethylated in both the cancer and normal
specimens. Therefore, this CpG site was excluded in
the following analysis.
The clinical characteristics of the NSCLC samples were
extracted from TCGA project. There is no significant
difference in age or gender between the cases and con-
trols (data not shown). The methylation percentages of
cg15020645, cg16970232, cg20311501, cg21634602 and
cg24332422 were dramatically different between the two
groups, especially in adenocarcinoma. The methylation
of all these five CpG sites were significantly different
between Ad and its counterparts according to the t-test
after FDR adjustment (P < 10−17), whereas only two CpG
sites (cg16970232, cg20311501) were significantly differentbetween Sc and its counterparts (P = 1.6 × 10−6 and 3.9 ×
10−3) (Table 4). In addition, logistic regression analysis also
supported the above results: the ORs in Ad were from
23.3 to 1.2 × 103, while those were from 0.15 to 7.54 in Sc
(Table 4). The AUCs of the five CpG methylation tests
were calculated to assess their prediction ability. As shown
in Table 4, each of the CpG sites in Ad was a much better
predictor (AUC: 0.71 to 0.73) than that in Sc (AUC: 0.45
to 0.61). The AUCs of the logistic prediction model based
on all the five CpG sites were 0.73 for Ad and 0.60 for Sc.
All the results above indicate that the APC methylation
test would have better performance in adenocarcinoma
than that in Sc, and therefore, the variation in the propor-
tions of Ad and Sc in the samples might affect the associ-
ation between APC methylation and NSCLC. Generally,
25 to 30% of lung cancers were Sc while 40% were Ad.
Thus, we resampled the Ad and Sc from TCGA data to
simulate the effect of the different ratios of Ad versus
Sc (Ad2Sc) at 2:1, 4:3, 3:4 and 1:2 on the OR of APC
methylation for NSCLC. The ORs dramatically varied
within group and between groups of the five CpGs by
10,000 times of resampling simulations (Additional file 1:
Table S3). As expected, cg16970232 and cg20311501, the
two significant sites in both Ad and Sc, were consistently




Figure 2 (See legend on next page.)
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Figure 2 Subgroup meta-analysis, cumulative analysis and summary receiver operating characteristics (SROC) estimation for the
relationship between APC promoter hypermethylation and non-small cell lung cancer (NSCLC). (A-D) Subgroup meta-analysis based on
age, control type, percentage of adenocarcinoma in total samples and primer set, respectively. (E) Cumulative meta-analysis of studies ordered
chronologically by publication year with random effects model. (F) SROC of APC methylation test in NSCLC.
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(Additional file 1: Table S3). Moreover, ORs from logistic
regression based on heterogeneous samples were signifi-
cantly greater than those of the autogenous samples in the
condition of Ad2Sc of 4:3, which was concordant with the
above subgroup meta-analysis (Additional file 1: Table S4).
Logistic interaction analysis among age and gender with
NSCLC did not show statistically significant interaction
between APC methylation and these covariates in the risk
of NSCLC (Additional file 1: Table S5).
Discussion
The APC gene has been reported as an important tumor
suppressor in colorectal cancer [30], and the aberrant of
APC methylation had been reported in numerics for
cancers, such as bladder [31], prostate [32], breast and
lung cancer [24]. However, the diagnostic role of the
methylation status of the APC gene in lung cancer lacks
quantitative assessment. We therefore performed an
integrated analysis to quantify the ability for the APC
promoter methylation test in NSCLC diagnosis, and a
significant association was identified between APC
methylation and NSCLC (OR = 4.67, P < 0.0001). Seven
imputed studies were filled when trim and fill tests
were performed to eliminate the influence of publication
bias on the random effects model, and the overall OR
(2.49, 95% CI: 1.18 to 5.26) was still significant, although it
was slightly smaller than that in the crude meta-analysis
(4.67, 95% CI: 2.66 to 8.22), indicating the existence of a
strong association between APC promoter methylation
and lung cancer. The pooled sensitivity, specificity andTable 3 Meta-regression analysis for the main potential
interference factors with random-effects model
Subgroup Coefficient (95% CI) P-value τ2
Sample type −1.03 (−2.4, 0.34) 0.14 0.90
Age −0.3 (−0.44, −0.16) 2.0 × 10−5 0.18
Proportion of stage I −0.01 (−0.05, 0.03) 0.608 0.79
Ratio of male to female −0.69 (−8.1, 6.71) 0.855 0.98
Detection methods −0.09 (−1.28, 1.1) 0.88 1.11
Study aim −0.82 (−2.05, 0.41) 0.19 1.07
Single/Multiple targets 1.05 (−0.71, 2.81) 0.243 1.01
Hetero/Autogenous control −1.25 (−2.35, −0.15) 0.026 0.89
Ad2Sc 0.44 (−0.56 , 1.44 ) 0.387 0.89
Primer set −1.02 (−1.02, −2.02) 0.05 0.35
Bold P-values lower than 0.05 indicate the item would be a
significant heterogeneity.AUC of the APC methylation test in the present meta-
analysis were 0.548, 0.78 and 0.64, respectively, which
revealed that APC methylation status is a good biomarker
in NSCLC diagnosis.
Integrated analysis showed that the age at diagnosis,
autogenous or heterogeneous control, the ratio of adeno-
carcinoma to squamous cell carcinoma, and primer set of
CpG sites were the most important heterogeneity sources,
while sample type (tissue or serum), proportion of males,
proportion of stage I, and detection methods could not
explain the heterogeneity.
Age was one of the most important heterogeneity sources
from meta-regression analysis (beta = −0.3, P = 2.0 × 10−5),
meanwhile, the OR in the younger subgroup (OR = 4.65)
was greater than that in the older subgroup (OR= 2.24).
However, TCGA NSCLC datasets demonstrated different
results. Furthermore, neither Ad nor Sc data supported age
affecting the OR of the APC methylation to the risk of
NSCLC in the logistic regression model (P > 0.05). Briefly,
much more evidence should be collected before making a
final decision.
As to the contribution of Ad2Sc, both subgroup ana-
lysis and TCGA analysis showed significantly greater OR
in the high Ad2Sc than that in the low Ad2Sc group,
which suggested the APC methylation test has better
diagnostic performance for adenocarcinoma.
Since the late 1980s, various studies have shown that the
same genetic/epigenetic alterations, such as DNA methy-
lation, in the primitive tumors were also found in the
circulating DNA of the patients with tumors [33-35].
Interestingly, in the present study, the OR of the serum
subgroup was greater than that of the tissue group and
the AUC of the APC methylation test for serum was
greater than that for tissue in both meta- and microarray
analysis, which indicated that the APC methylation test
should be a promising serum biomarker for NSCLC
diagnosis.
Meta-analysis has been widely applied in SNP-disease
risk association studies because SNPs have specific gen-
ome location. Meta-analysis is also gradually starting to
boom in the realm of DNA methylation. Here, the primers
for methylation detection have been considered when
extracting information from studies; however, they have
sometimes been difficult to analyze in the subsequent
subgroup or meta-regression analysis due to the great
diversity of the primers used in each individual article.
For example, at least three different primer sets were
observed in the 17 studies we selected for meta-analysis
Table 4 Differential APC methylation, odds ratio, area under the curve (AUC) between adenocarcinoma, squamous cell carcinoma and their counterparts
Adenocarcinoma Squamous Cell Carcinoma
CpG site MCaM(N = 535)
MCoM
(N = 56) P-value
a FDRa ORb P-valueb 95% CIb AUCb MCaM(N = 386)
MCoM
(N = 70) P-value
a FDRa ORb P-valueb 95% CIb AUC†
cg15020645 0.26(40.7%) 0.13(0%) 3.5 × 10−32 1.0 × 10−31 190.6 7.7 × 10−6 22.65 to 2,321 0.72 0.13(14.77%) 0.11(0%) 0.087466 0.131199 3.16 0.406 0.28 to 68.72 0.61
cg16970232 0.3(45.2%) 0.11(0%) 5.0 × 10−38 3.0 × 10−37 108.9 5.1 × 10−6 17.64 to 1,043 0.73 0.15(18.91%) 0.09(0%) 2.7 × 10−7 1.6 × 10−6 7.54 0.035 1.39 to 64.07 0.45
cg20311501 0.33(48.4%) 0.16(5.3%) 1.4 × 10−22 2.1 × 10−22 61.56 4.96 × 10−6 11.94 to 420 0.73 0.18(19.95%) 0.14(0%) 0.001955 0.003909 2.48 0.257 0.57 to 13.74 0.49
cg21634602 0.33(47.4%) 0.16(7.1%) 3.6 × 10−17 4.3 × 10−17 23.34 3.6 × 10−5 5.75 to 116.0 0.71 0.16(20.47%) 0.14(7.14%) 0.222306 0.266767 1.27 0.726 0.35 to 5.42 0.53
cg24332422 0.26(40.5%) 0.16(0%) 1.0 × 10−26 2.0 × 10−26 223.6 2.81 × 10−5 21.11 to 3,463 0.71 0.16(17.36%) 0.15(0%) 0.338755 0.338755 1.6 0.656 0.23 to 14.30 0.52
MCaM, MCoM represent the mean of case methylation (Beta) and mean of control methylation (Beta). Methylation levels are calculated with formula: Beta = (M/M + U).
aP-values are from t-test or Wilcoxon rank-sum test after false discovery rate (FDR adjustment). The t-test will be chose when the variable is normally distributed, or else the rank-sum test will be chose. Significant
P-values after FDR are bolded which indicate significant different methylation between case and control.
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http://www.clinicalepigeneticsjournal.com/content/6/1/5(Additional file 1: Table S2). Moreover, in order to expati-
ate on the divergence of different CpG sites, we collected
the methylation signals of five CpGs from the methylation
27 K and 450 K microarray datasets from TCGA project
(Ad and Sc). It was found that the ORs of the five CpG
sites were dramatically different (Table 4). Subgroup ana-
lysis further showed significantly different ORs in different
primer sets. This reminds us that future DNA methylation
detection in case-control studies should be designed more
accurately and comprehensively for certain CpG sites or
blocks and the location information should be clearly
noted when published in order to facilitate the re-analysis
of the published data.
Conclusion
In conclusion, this integrated analysis of the pooled
data provides strong evidence that the methylation sta-
tus of the APC promoter is strongly associated with
NSCLC, especially for adenocarcinoma. Therefore, the
APC methylation test could be a promising diagnostic
biomarker which could be applied in the clinical diagnosis
of lung adenocarcinoma with remote non-invasive media
detection.
Methods
Search strategy, selection of studies and data extraction
This pooled study involved searching a range of comput-
erized databases, including PubMed, Cochrane Library,
OVID Medline and TMC ProSearch for articles pub-
lished in English or Chinese by September 2013. The
study used a subject and text word strategy with (APC
OR BTPS2 OR DP2 OR DP2.5 OR DP3 OR PPP1R461)
AND (Lung OR NSCLC) AND (cancer OR neoplasm))
as the primary search terms. Wildcard character of star,
dollar or some other truncations were applied according
to the rules of the databases to allow effective article
collection.
Two independent reviewers (Guo, Tan) screened the
titles and abstracts derived from the literature search to
identify relevant studies. The following types of studies
were excluded: animal experiments, case reports, reviews
or meta-analyses and studies of non-case-control studies
or studies with insufficient data or those proving inaccess-
ible after making contact with the authors. The remaining
articles were further examined to see if they met the inclu-
sion criteria: 1) the patients had to be diagnosed with
NSCLC (Ad and Sc), 2) the studies had to contain APC
gene promoter methylation data from tissue, blood or
serum, 3) the studies had to be case-control studies which
included tissue-tissue, blood-blood or serum-serum in
case and controls respectively. The reference sections
of all retrieved articles were searched to identify further
relevant articles. Potentially relevant papers were obtained
and the full text articles were screened for inclusionby two independent reviewers (Guo, Tan). Disagreements
were resolved by discussion with KX, JJW, and JHW.
Included studies were summarized in data extraction
forms. Authors were contacted when relevant data were
missing. The name of the first author, year of publication,
sample size, age (mean or median), gender proportion
(male/female, M2F), the proportion of TNM stage I sam-
ples (proportion of early stage of NSCLC samples), publi-
cation aim (for diagnosis or not), analyzing multiple genes
or not (one or more genes detected simultaneously in
studies design), control type (autogenous or heteroge-
neous counterpart) and methylation status of the APC
promoter in human NSCLC and normal or control tissues
were extracted.
Meta-analysis and SROC analysis
Data were analyzed and visualized mainly using R Soft-
ware (R version 2.15.3) including meta, metefor and mada
packages. The strength of association was expressed as
pooled odds ratio (OR) with corresponding 95% confi-
dence intervals (95% CI). Data were extracted from the
original studies and recalculated if necessary. Heterogen-
eity was tested using the I2 statistic with values over 50%
and Chi-squared test with P ≤ 0.1 indicating strong hetero-
geneity between the studies [36]. Tau-squared (τ2) was
used to determine how much heterogeneity was explained
by subgroup differences. The data were pooled using the
DerSimonian and Laird random effects model (I2 > 50%,
P ≤ 0.1) or fixed effects model (I2 < 50%) according to
heterogeneity statistic I2 [37]. A two-sided P ≤ 0.05 was
considered significant without special annotation. Random
effects meta-regression, was employed to determine how
much of the heterogeneity (between-study variance) is
explained by the explanatory variables when the hetero-
geneity was significant [38]. Nine variables were analyzed
in meta-regression, including control types (autogenous
and heterogeneous), gender proportion, proportion of
TNM stage I samples, mean or median age (> 65 or ≤ 65),
single or multiple target detection, sample types (serum
or tissue), methylation detection methods (MSP, qMSP),
study designs (diagnosis or non-diagnosis) and primer
sets. Sensitivity analyses were performed to assess the con-
tributions of single studies to the final results with the
abandonment of one article each time. Publication bias
was analyzed by funnel plot with mixed-effects version of
the Egger test. If bias was suspected, the conventional
meta-trim method was used to re-estimate the effect size.
Compared with traditional SNP association studies,
methylation-associated research might be involved with
different methylation-definition thresholds. In these cases,
traditional weighted averages (pooled sensitivity and speci-
ficity) would not reflect the overall accuracy of the test,
because the extremes of threshold criteria could skew
the distribution, known as the threshold effect [39]. Thus,
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http://www.clinicalepigeneticsjournal.com/content/6/1/5SROC analysis was applied to meta-analysis of diagnostic
tests [39,40]. The SROC curve shows the performance
of the diagnostic ability of APC methylation to NSCLC.
Each study produces values for sensitivity, specificity
and therefore true positive rate (TPR) and false positive
rate (FPR), and the plots were placed over the TPR and
FPR points to form a smooth curve. A linear regression
model was selected to fit the SROC curve where sensi-
tivity and (1-specificity) are transformed into complex
logarithmic variables. The exact AUC for the SROC
function was used to assess the accuracy of the test [39].
TCGA data extraction and analysis
DNA methylation information for NSCLC, which included
two sets of samples (535 Ads and 50 controls, and 385 Scs
and 67 controls), was collected from TCGA project includ-
ing methylation 27 K and 450 K datasets [http://cancergen-
ome.nih.gov/]. The estimation of methylation for each CG
probe was calculated with the traditional function:
beta ¼ max M; 0ð Þ
max M; 0ð Þ þ max U; 0ð Þ
M and U represent the mean signal intensities for
about 30 replicate methylated (M) and unmethylated (U)
probes on the array. The methylation signals of the
25,978 shared CpG sites by 27 K and 450 K datasets
were extracted and the methylation status of each probe
was defined according to the beta-value. The CpG site
will be considered methylated when the beta-value is
greater than the empirical threshold of 0.3 for tissue
data [41]. Six CpG sites located in the promoter region
of the APC gene (cg01240931, cg15020645, cg16970232,
cg20311501, cg21634602 and cg24332422) were taken as
the object of study (Additional file 1: Table S1). Adjust-
ment for multiple testing of differential methylation was
conducted with the method of Benjamini and Hochberg at
the 5% FDR level.
Additional files
Additional file 1: Table S1. TCGA probe information in this study.
Table S2. Three kinds of primers of the present 17 studies. Table S3. The
fluctuation of odds ratio in vignettes of different proportion of Ad. Table S4.
Odds ratio difference between heterogeneous and autogenous samples in
vignettes of different proportion of Ad. Table S5. Interaction estimation
between CpG methylation and age, gender, TNM in Ad and Sc.
Additional file 2: Figure S1. Funnel plot to diagnosis of the
publication bias. Figure S2. Combined estimates for the association
between APC methylation and NSCLC after trim-fill treatment. Figure S3.
Sensitivity analyses of the overall effect by omitting a single study.
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